{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=16", "query": { "intervention": "Advanced therapy", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 6312, "total_pages": 632, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Advanced+therapy&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T12:47:28.120Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02315625", "title": "Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Neuroendocrine Carcinoma", "Neuroendocrine Neoplasms", "Carcinoma, Neuroendocrine", "Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2015-04-08", "completion_date": "2019-05-22", "has_results": true, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-11-13T12:47:28.120Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315625" }, { "nct_id": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma", "Gastric Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "Pancreas Cancer", "Melanoma", "NSCLC", "Urothelial Carcinoma", "Cervical Cancer", "Microsatellite Instability", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "FT500", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-02-15", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-11-13T12:47:28.120Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03841110" }, { "nct_id": "NCT06364358", "title": "Interactive Computer-adaptive Chronic Kidney Disease Education Program", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Kidney Diseases", "Hypertension" ], "interventions": [ { "name": "Computerized CKD Education", "type": "BEHAVIORAL" }, { "name": "Usual Hospital Care", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 120, "start_date": "2023-05-31", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-11-13T12:47:28.120Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06364358" }, { "nct_id": "NCT04906876", "title": "A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Soft Tissue Sarcoma", "Metastatic Sarcoma", "Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Leiomyosarcoma", "Liposarcoma", "Angiosarcoma", "Synovial Sarcoma", "Rhabdomyosarcoma", "Spindle Cell Sarcoma", "High Grade Sarcoma", "Bone Sarcoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "9-ING-41", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 0, "start_date": "2021-09", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2021-07-28", "last_synced_at": "2026-11-13T12:47:28.120Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906876" }, { "nct_id": "NCT02226276", "title": "Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bone Metastases", "HER2-positive Breast Cancer", "Liver Metastases", "Lung Metastases", "Recurrent Breast Cancer", "Soft Tissue Metastases", "Stage IV Breast Cancer" ], "interventions": [ { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "copper Cu 64-DOTA-trastuzumab", "type": "RADIATION" }, { "name": "ado-trastuzumab emtansine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2015-02-25", "completion_date": "2027-09-07", "has_results": true, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-13T12:47:28.120Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02226276" }, { "nct_id": "NCT00396591", "title": "AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2006-10", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2013-01-10", "last_synced_at": "2026-11-13T12:47:28.120Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00396591" }, { "nct_id": "NCT00112060", "title": "A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "PT-523 for Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-04", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2014-03-31", "last_synced_at": "2026-11-13T12:47:28.120Z", "location_count": 4, "location_summary": "Miami, Florida • Chicago, Illinois • Durham, North Carolina + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112060" }, { "nct_id": "NCT02250326", "title": "Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "nab-paclitaxel IV", "type": "DRUG" }, { "name": "CC-486", "type": "DRUG" }, { "name": "Duravalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2015-01-07", "completion_date": "2023-08-17", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-11-13T12:47:28.120Z", "location_count": 9, "location_summary": "San Francisco, California • New Britain, Connecticut • Athens, Georgia + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Athens", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02250326" }, { "nct_id": "NCT04812535", "title": "Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SCC - Squamous Cell Carcinoma of Skin" ], "interventions": [ { "name": "Vilobelimab", "type": "DRUG" }, { "name": "Vilobelimab + pembrolizumab combination therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InflaRx GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-03-31", "completion_date": "2024-06-04", "has_results": true, "last_update_posted_date": "2025-02-11", "last_synced_at": "2026-11-13T12:47:28.120Z", "location_count": 6, "location_summary": "La Jolla, California • Aurora, Colorado • Miami, Florida + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04812535" }, { "nct_id": "NCT02387125", "title": "Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Melanoma", "Non-small Cell Lung Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "CMB305", "type": "BIOLOGICAL" }, { "name": "G100", "type": "BIOLOGICAL" }, { "name": "Metronomic CPA", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 79, "start_date": "2015-02-28", "completion_date": "2019-03-29", "has_results": false, "last_update_posted_date": "2020-07-01", "last_synced_at": "2026-11-13T12:47:28.120Z", "location_count": 8, "location_summary": "Santa Monica, California • New Haven, Connecticut • Tampa, Florida + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387125" } ] }